Study guide
1.3 Assessment of Risk
PTCB Hazardous Drug Management Certificate Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
0.1 Exam Facts, Format & Eligibility 0.2 Content Outline, Scoring & Registration 0.3 USP <800> Big Picture & How to Use This Guide
2 USP <800> Program Administration
1.1 USP <800> Scope, Purpose & Enforcement 1.2 The NIOSH Hazardous Drug List (2024 Update) 1.3 Assessment of Risk 1.4 Designated Person, SOPs & the Hierarchy of Controls
3 Training, Compliance & Recordkeeping
2.1 Training Requirements & Medical Surveillance 2.2 Hazard Communication, SDS & OSHA Requirements 2.3 Recordkeeping & Professional Guidelines
4 Primary Engineering Controls
3.1 Containment Primary Engineering Controls (C-PEC): BSCs & CACIs 3.2 Closed System Transfer Devices (CSTDs) 3.3 Nonsterile Controls and the C-SCA Distinction
5 Secondary Engineering Controls & Facility Design
4.1 Containment Secondary Engineering Controls (C-SEC): Negative Pressure & Air Exchange 4.2 Facility Layout: Storage, Unpacking & Sink Placement 4.3 Certification, ISO Classes & Emergency Equipment
6 Facility Cleaning Procedures
5.1 The Four-Step Cleaning Process 5.2 Wipe Sampling & Action Levels 5.3 Hazardous Waste Disposal & RCRA
7 Spill Response & Cleaning PPE
6.1 Spill Kits & Spill Response Procedures 6.2 PPE During Cleaning: Glove Change Frequency & Disposal
8 Dispensing & the Compounding Interface
7.1 USP <795>/<797> Interface for Hazardous Drugs 7.2 High-Risk Oral Hazardous Drugs 7.3 Tablet Splitting & Crushing Restrictions
9 Counting, Packaging & Patient Counseling
8.1 Counting, Packaging & Dedicated Equipment 8.2 Patient Counseling & Unit-Dose Labeling
10 PPE: Gloves, Gowns & Task-Based Selection
9.1 ASTM D6978 Chemotherapy Gloves & Double Gloving 9.2 Chemo Gowns & Gown Change Frequency 9.3 Task-Based PPE Selection
11 Respiratory Protection, Eye Protection & PPE Sequencing
10.1 Respiratory & Eye/Face Protection 10.2 Donning & Doffing Sequence
12 Transport & Receiving
11.1 Receiving Hazardous Drug Shipments 11.2 Internal Transport & Storage 11.3 Damaged/Leaking Shipments & Chain of Custody
13 Exam Readiness & Final Review
12.1 Domain-by-Domain Quick Review 12.2 Common Exam Traps & Final Checklist
1.3 Assessment of Risk
Key Takeaways Explain This Topic AI
An Assessment of Risk (AoR) is a documented, task-specific risk evaluation under USP <800> — not a blanket exemption from the chapter's requirements.
AoR eligibility is generally limited to final dosage forms requiring only counting, weighing, or repackaging; compounding and manipulation activities remain outside AoR eligibility.
Even when an AoR justifies reduced containment, USP <800> requires at minimum single chemotherapy gloves for the eligible activity.
Antineoplastic drugs requiring manipulation and NIOSH Table 1 drugs generally cannot use an AoR to bypass required primary engineering controls for compounding.
Last updated: July 2026
Assessment of Risk
Quick Answer: An Assessment of Risk (AoR) is a documented, facility-level process USP <800> permits for certain lower-risk hazardous drug (HD) activities — primarily final dosage forms that require only counting, weighing, or repackaging, not compounding or manipulation — to determine whether alternative containment strategies and work practices can be used instead of the full engineering-control requirements of the chapter. An AoR must be documented, must use at minimum single chemotherapy gloves, and cannot be used to bypass primary engineering controls for compounding antineoplastic drugs or NIOSH Table 1 drugs.
The Assessment of Risk is USP <800>'s built-in escape valve — a way to avoid over-engineering a low-risk task like counting tablets into a vial, while still requiring facilities to justify and document that decision. It is also one of the most frequently misapplied provisions in real practice, which is exactly why it shows up on the exam.
What an AoR Is — and Is Not
An AoR is not a blanket exemption from <800>. It is a structured, documented risk evaluation a facility performs for a specific, eligible activity to decide whether reduced containment is appropriate. The facility must consider factors such as:
- The type of HD and its NIOSH table classification
- The dosage form and whether it requires manipulation
- The risk of exposure during the specific task
- Packaging and any manufacturer-specific handling information
If the facility completes this evaluation and documents its rationale, it may implement alternative containment strategies or PPE for that specific task — but the documentation itself is a requirement, not optional paperwork.
Which Activities Are Eligible
The clearest, most heavily tested eligibility line is manipulation :
Activity AoR-Eligible?
Counting whole, intact oral HD tablets from a manufacturer bottle into a dispensing vial Yes — no manipulation involved
Weighing or repackaging a final dosage form without altering it Yes
Compounding a sterile antineoplastic IV admixture No — compounding of an antineoplastic requires full primary/secondary engineering controls
Splitting or crushing an HD tablet No — this is manipulation, not simple counting/repackaging
Preparing a compounded nonsterile or sterile HD preparation No — compounded preparations are excluded from using an AoR in place of required engineering controls
Exam trap: an AoR can reduce containment expectations for counting/repackaging final dosage forms, but it can never substitute for a certified primary engineering control (a biological safety cabinet or compounding aseptic containment isolator) when an antineoplastic drug is actually being compounded or manipulated. If a scenario describes compounding, manipulation, or an antineoplastic preparation, the AoR pathway is not available to skip the required engineering controls.
The Minimum Floor: Single Chemo Gloves
Even when an AoR justifies reduced containment for an eligible activity, USP <800> sets a floor: at minimum, single chemotherapy gloves meeting the required testing standard must still be worn. An AoR can reduce some requirements (for example, whether a dedicated ventilated cabinet is required for counting tablets), but it cannot eliminate glove protection entirely. A facility that concludes "no PPE needed" for HD tablet counting, based on an AoR, has misapplied the tool.
Table 1 vs. Table 2 and AoR Eligibility
Because Table 1 drugs (MSHI and/or NTP/IARC carcinogen classification) carry the strongest hazard evidence, they are poor — often ineligible — candidates for AoR-based containment reduction, especially for any activity beyond simple counting/repackaging of an unaltered final dosage form. Table 2 drugs, which meet a NIOSH hazard criterion without carcinogen classification, are more commonly the drugs a facility can successfully justify handling with an AoR-based alternative approach. This is one more reason the Table 1/Table 2 distinction from the NIOSH list (covered in the previous section) is foundational — you cannot correctly reason through an AoR question without first knowing which table a drug falls into.
Exam Scenario
A retail pharmacy technician routinely counts an oral oncology tablet — a final dosage form, not compounded — from a stock bottle into a vial for dispensing. The pharmacy has completed and documented an Assessment of Risk for this specific task, concluding that a dedicated ventilated device is not required for simple counting of this intact tablet, but requiring single chemotherapy gloves and a dedicated counting tray at minimum. A new technician assumes the AoR means no special handling is needed at all and counts the tablets bare-handed with the store's shared counting tray. This violates the documented AoR itself — the AoR reduced some requirements but preserved others (gloves, dedicated equipment), and it never eliminated PPE.
Key Takeaways
An AoR is a documented, task-specific risk evaluation — not a blanket exemption from USP <800>.
AoR eligibility is generally limited to final dosage forms needing only counting, weighing, or repackaging — not compounding or manipulation.
At minimum, single chemotherapy gloves are still required even when an AoR justifies reduced containment elsewhere.
Antineoplastic drugs requiring manipulation and NIOSH Table 1 drugs generally cannot use an AoR to bypass required primary engineering controls for compounding.